Technical Analysis for GPCR - Structure Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | N/A | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -0.13% | |
| Gapped Up | Strength | -0.13% | |
| Down 3 Days in a Row | Weakness | -0.13% | |
| 20 DMA Resistance | Bearish | -1.02% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Rose Above 20 DMA | about 15 hours ago |
| Rose Above Previous Day's High | about 15 hours ago |
| Rose Above 10 DMA | about 15 hours ago |
| Up 5% | about 15 hours ago |
| Up 3% | about 15 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: Unknown
Structure Therapeutics Inc. Description
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Biology Molecular Biology Obesity Signal Transduction Chronic Disease Pulmonary Arterial Hypertension Diabetes Mellitus Idiopathic Pulmonary Fibrosis Biochemistry Glucagon Receptor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.5 |
| 52 Week Low | 20.8001 |
| Average Volume | 70,872 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 23.89 |
| 10-Day Moving Average | 23.08 |
| Average True Range | 2.39 |
| RSI | 39.39 |
| ADX | 26.04 |
| +DI | 19.82 |
| -DI | 12.68 |
| Chandelier Exit (Long, 3 ATRs) | 21.34 |
| Chandelier Exit (Short, 3 ATRs) | 27.96 |
| Upper Bollinger Bands | 26.33 |
| Lower Bollinger Band | 21.44 |
| Percent B (%b) | 0.2 |
| BandWidth | 20.46 |
| MACD Line | -0.21 |
| MACD Signal Line | 0.04 |
| MACD Histogram | -0.2444 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.64 | ||||
| Resistance 3 (R3) | 25.97 | 25.23 | 25.11 | ||
| Resistance 2 (R2) | 25.23 | 24.41 | 25.07 | 24.93 | |
| Resistance 1 (R1) | 23.83 | 23.91 | 23.46 | 23.50 | 24.75 |
| Pivot Point | 23.09 | 23.09 | 22.91 | 22.93 | 23.09 |
| Support 1 (S1) | 21.69 | 22.27 | 21.32 | 21.36 | 20.11 |
| Support 2 (S2) | 20.95 | 21.77 | 20.79 | 19.93 | |
| Support 3 (S3) | 19.55 | 20.95 | 19.76 | ||
| Support 4 (S4) | 19.22 |
